Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | NAMPT | P43490 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5572067 | 0.87 | KMT2A (0.54) | HTTNAMPTTDP1KMT2AMEN1 | |
| SCHEMBL28273729 | 0.85 | TDP1 (0.65) | HTTNAMPTTDP1KMT2AMEN1 | |
| SCHEMBL4285086 | 0.85 | TDP1 (0.65) | HTTNAMPTTDP1KMT2AMEN1 | |
| SCHEMBL28165171 | 0.85 | TDP1 (0.65) | HTTNAMPTTDP1KMT2AMEN1 | |
| SCHEMBL10739485 | 0.85 | TDP1 (0.65) | HTTNAMPTTDP1KMT2AMEN1 | |
| SCHEMBL24176160 | 0.85 | TDP1 (0.65) | HTTNAMPTTDP1KMT2AMEN1 | |
| SCHEMBL10739048 | 0.85 | TDP1 (0.65) | HTTNAMPTTDP1KMT2AMEN1 | |
| SCHEMBL8397091 | 0.84 | HTT (0.62) | HTTNAMPTTDP1KMT2AMEN1 | |
| SCHEMBL1474054 | 0.82 | HTT (0.60) | HTTNAMPTTDP1KMT2AMEN1 | |
| SCHEMBL8391321 | 0.82 | HTT (0.60) | HTTNAMPTTDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125729-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | Arete Therapeutics, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080207908-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC | 2008-08-28 | — | — | US | claimed |
| WO-2008094862-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| EP-2125729-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | Arete Therapeutics, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080207908-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC | 2008-08-28 | — | — | US | disclosed |
| WO-2008094862-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-0328830-B1 | 4-Heteropentacyclic-4- N-(phenyl)amido piperidine compounds | OHMEDA PHARMA PROD (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0277794-B1 | N-heterocyclic-N-(4-piperidyl) amides | OHMEDA PHARMA PROD (US) | 1994-04-20 | — | — | EP | disclosed |
| US-5214055-A | Analgesics, psychological disorders, anxiolytic agents | ADIR ET COMPAGNIE (FR) | 1993-05-25 | — | — | US | disclosed |
| US-5189045-A | Antiserotonine agent | ADIR ET COMPAGNIE (FR) | 1993-02-23 | — | — | US | disclosed |
| EP-0160422-B1 | N-ARYL-N-(4-PIPERIDINYL)AMIDES AND PHARMACEUTICAL COMPOSITIONS AND METHODS EMPLOYING SUCH COMPOUNDS | Anaquest, Inc. (US) | 1992-01-08 | — | — | EP | disclosed |
| US-4225606-A | ANTIARRHYTHEMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-09-30 | — | — | US | disclosed |
| US-4208418-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-06-17 | — | — | US | disclosed |
| US-4198411-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-15 | — | — | US | disclosed |
| US-4197303-A | ANTIARRHYTHMIA AGENTS, ALKOXYCARBONYL ON 4-POSITION OF PIPERIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4197304-A | ANTIARRHYTHMIA AGENTS, N-PYRIDINYL-N-(4-ALKYLPIPERIDINYL)THIENYLACETAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4196210-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-01 | — | — | US | disclosed |
| US-4157393-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-06-05 | — | — | US | disclosed |
| US-4151286-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-04-24 | — | — | US | disclosed |
| US-4126689-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207908-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | UMPS, CPS1, NISCH | HTT 633/4885NAMPT 284/4885TDP1 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.